Columbia Trust Co 01012016 cut its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 17.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,101 shares of the biopharmaceutical company’s stock after selling 1,761 shares during the quarter. Columbia Trust Co 01012016’s holdings in Pfizer were worth $331,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Harbor Investment Advisory LLC increased its holdings in Pfizer by 3.6% during the fourth quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock valued at $1,229,000 after buying an additional 825 shares during the period. BancFirst Trust & Investment Management increased its holdings in Pfizer by 2.3% during the first quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 398 shares during the period. Secure Asset Management LLC increased its holdings in Pfizer by 3.5% during the fourth quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock valued at $811,000 after buying an additional 537 shares during the period. Range Financial Group LLC boosted its stake in Pfizer by 2.8% in the first quarter. Range Financial Group LLC now owns 37,010 shares of the biopharmaceutical company’s stock valued at $1,510,000 after acquiring an additional 1,024 shares in the last quarter. Finally, Allred Capital Management LLC boosted its stake in Pfizer by 1.9% in the fourth quarter. Allred Capital Management LLC now owns 20,425 shares of the biopharmaceutical company’s stock valued at $1,047,000 after acquiring an additional 387 shares in the last quarter. 67.80% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on PFE shares. Bank of America lowered their target price on shares of Pfizer from $50.00 to $45.00 and set a “neutral” rating for the company in a research note on Friday, April 21st. Barclays lowered their target price on shares of Pfizer from $43.00 to $40.00 in a research note on Wednesday, May 3rd. UBS Group lowered their target price on shares of Pfizer from $41.00 to $39.00 in a research note on Friday, May 5th. JPMorgan Chase & Co. set a $45.00 target price on shares of Pfizer in a research note on Monday, February 27th. Finally, Jefferies Financial Group assumed coverage on shares of Pfizer in a research note on Monday, March 6th. They set a “hold” rating and a $43.00 price objective for the company. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $47.33.
Pfizer Stock Down 0.4 %
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The company had revenue of $18.28 billion during the quarter, compared to analysts’ expectations of $16.49 billion. During the same quarter in the previous year, the company earned $1.62 earnings per share. The firm’s revenue for the quarter was down 28.8% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 3.35 earnings per share for the current year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.23%. Pfizer’s dividend payout ratio is currently 32.28%.
Insider Transactions at Pfizer
In related news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction dated Monday, May 8th. The stock was acquired at an average price of $38.58 per share, with a total value of $38,580.00. Following the completion of the purchase, the director now directly owns 6,000 shares of the company’s stock, valued at $231,480. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.05% of the company’s stock.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Get a free research report on Pfizer from StockNews.com
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Darden Restaurants: Ring The Register Or Time To Buy?
- United Airlines: Cleared For Takeoff As It Approaches Buy Point?
- KB Home Hits Peak: Pullback Imminent
- Five stocks we like better than Pfizer
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
